🇺🇸 Vfend (voriconazole) tablet in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 11

Most-reported reactions

1. Liver Disorder — 2 reports (18.18%)
2. Abdominal Pain Upper — 1 report (9.09%)
3. Alanine Aminotransferase Increased — 1 report (9.09%)
4. Anaemia — 1 report (9.09%)
5. Aspartate Aminotransferase Increased — 1 report (9.09%)
6. Bk Virus Infection — 1 report (9.09%)
7. Bronchopulmonary Aspergillosis — 1 report (9.09%)
8. Cerebral Aspergillosis — 1 report (9.09%)
9. Chronic Graft Versus Host Disease — 1 report (9.09%)
10. Convulsion — 1 report (9.09%)

Source database →

Frequently asked questions

Is Vfend (voriconazole) tablet approved in United States?

Vfend (voriconazole) tablet does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Vfend (voriconazole) tablet in United States?

Seoul National University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.